THIRD QUARTER HIGHLIGHTS Production and Fourth Quarter Expectations: The Company produced 87,020 ounces of gold in the third quarter, in line with expectations and operating plans, which fully support ...

TAPS+ enables simultaneous detection of methylation and genetic variants, unlocking new insights for precision oncology and translational research. Preserves DNA integrity in challenging clinically ...

Record free cash flow of approximately $700 million and achieved net cash position Increased 2025 share buyback target by 20% ...

NeoGenomics’ third quarter results were met with a negative market reaction, as shares declined following the announcement. Management attributed the quarter’s performance to robust growth in clinical ...

Researchers set a new world record for the fastest DNA sequencing, completing a whole genome in under four hours—a ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2025 following ...

"These results are encouraging, highlighting TET2-mutated clonal hematopoiesis as a potential biomarker to select patients who are more likely to respond to immunotherapy," said Padmanee Sharma, M.D., ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q3 CY2025 results , with sales up 11.9% year on year ...

NeoGenomics Inc. ( (NEO) ) has released its Q3 earnings. Here is a breakdown of the information NeoGenomics Inc. presented to its investors.Elevate Your Investing Strategy: Take advantage of TipRanks ...

According to the Government’s portal (“Elisa del Plan de Recuperación”), as of August 31, 2026, a total of €79.854 billion has been reserved for various projects between the Central Administration and ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...